Medications
USA
Biologics and infusion treatments for children
Learn about biologic medications and infusion treatments for children with Crohn’s disease and ulcerative colitis in the USA, including how they work, what to expect, side effects, costs, and insurance coverage.

Biologic medications are an important treatment option for children living with Crohn’s disease and ulcerative colitis (IBD). If your child’s current medication is not controlling their symptoms, or their disease is more severe, their paediatric gastroenterologist may recommend a biologic treatment.
Starting a new medication can feel overwhelming for families. Understanding how biologics work, how treatments are given, and what to expect can help you and your child feel more prepared.
💊 What Are Biologics?
Biologics are medicines made from living organisms that target specific parts of the immune system involved in inflammation. Unlike some traditional IBD medications, which affect the immune system more broadly, biologics target particular proteins or pathways that contribute to inflammation in the digestive tract.
They can help reduce inflammation, improve symptoms, support healing of the bowel lining, and maintain remission.
Biologics may be recommended when:
Other medications have not controlled your child’s IBD.
Your child has moderate to severe Crohn’s disease or ulcerative colitis.
Your child has complications or a higher risk of disease progression.
Their gastroenterologist believes early biologic treatment may offer better disease control.
Biologics do not cure IBD, but they can help many children achieve and maintain remission.
🧬 Which biologics are used for children in the USA?
Several biologic medications are used to treat paediatric IBD in the United States. The most appropriate option depends on your child’s diagnosis, age, disease severity, medical history, and previous treatments.
Common biologic options include:
Infliximab (Remicade and biosimilars): An anti-TNF medication commonly used for paediatric Crohn’s disease and ulcerative colitis. It is given through an intravenous (IV) infusion.
Adalimumab (Humira and biosimilars):
